FDA approves Journavx (Suzetrigine) as the first non-opioid treatment for moderate to severe acute pain
Abstract
Acute pain is a sudden-onset condition that typically lasts less than 6 months and can significantly affect daily life, well-being, and healthcare costs. Management options include nonsteroidal anti-inflammatory drugs such as aspirin and ibuprofen, aceta-minophen, corticosteroids, and opioids. In severe cases, opioids may be necessary, but their use is limited by side effects, such as hypoventilation, nausea, vomiting, constipation, CNS depression, and renal dysfunction [1] . Opioids continue to play a key role in pain management, but their use must minimize risks while maximizing benefits.
Read the paper
Related studies
- Noninvasive and Point-of-Care Surface-Enhanced Raman Scattering (SERS)-Based Breathalyzer for Mass Screening of Coronavirus Disease 2019 (COVID-19) under 5 min
- De Novo Transcriptome Analysis and Detection of Antimicrobial Peptides of the American Cockroach Periplaneta americana (Linnaeus)
- Molecular Characterization and Expression Profiling of Tomato GRF Transcription Factor Family Genes in Response to Abiotic Stresses and Phytohormones
- Assembly of Tight Junction Strands: Claudin-10b and Claudin-3 Form Homo Tetrameric Building Blocks that Polymerise in a Channel-Independent Manner
- Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease‐associated variants, common sequence variants, and results from newborn screening
- Machine Learning-Based SERS Chemical Space for Two-Way Prediction of Structures and Spectra of Untrained Molecules
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.